A study highlights insufficient standardized safety and efficacy assessments for FDA-cleared AI/ML medical devices.
Key Details
- 1Cross-sectional analysis of FDA-cleared AI/ML-enabled devices was conducted.
- 2The study found lack of standardized efficacy and safety reporting in device clearance.
- 3Suggested need for dedicated regulatory pathways and post-market AI/ML safety surveillance.
- 4Study was published in JAMA Health Forum and led by Dr. Ravi B. Parikh.
Why It Matters
As imaging AI tools increasingly enter clinical use, robust regulatory oversight is critical for patient safety and clinician trust. Gaps in FDA reporting and surveillance could impact the safe integration of AI in radiology practice.
Source
EurekAlert
Related News
•EurekAlert
AI Model Outperforms Breast Density in 5-Year Cancer Risk Stratification
An AI model using mammogram images predicts 5-year breast cancer risk more accurately than traditional breast density assessment.
•EurekAlert
AI-Based Imaging Biomarker for Chronic Stress Validated on Chest CT
A deep learning model has identified and validated the first imaging biomarker for chronic stress using adrenal gland measurements from routine chest CT scans.
•EurekAlert
UK Researchers Launch Unbiased AI Testing Platform for Diabetic Retinopathy Screening
Researchers unveiled a new independent platform for fair, large-scale evaluation of commercial AI algorithms detecting diabetic eye disease within the NHS.